Full Text
HT3 A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS

Abstract

Authors

R Mallick GP Sillup

Back to Volume 12, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×